Status:
ACTIVE_NOT_RECRUITING
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Conditions:
Unresectable Colorectal Cancer
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients...
Eligibility Criteria
Inclusion
- Unresectable advanced or recurrent colorectal cancer
- Life expectancy of at least 3 months
- Patients with ECOG performance status 0 or 1
Exclusion
- Patients with severe complication
- Patients with multiple primary cancers
Key Trial Info
Start Date :
September 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2027
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT06540261
Start Date
September 23 2021
End Date
December 31 2027
Last Update
September 19 2024
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
2
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
3
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
4
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan